Cellectar Biosciences (CLRB) Competitors $4.85 +0.15 (+3.19%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$4.90 +0.06 (+1.13%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. LVTX, ATHE, TELO, RNTX, KALA, LTRN, KZR, OKUR, ESLA, and BDRXShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include LAVA Therapeutics (LVTX), Alterity Therapeutics (ATHE), Telomir Pharmaceuticals (TELO), Rein Therapeutics (RNTX), KALA BIO (KALA), Lantern Pharma (LTRN), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors LAVA Therapeutics Alterity Therapeutics Telomir Pharmaceuticals Rein Therapeutics KALA BIO Lantern Pharma Kezar Life Sciences OnKure Therapeutics Estrella Immunopharma Biodexa Pharmaceuticals Cellectar Biosciences (NASDAQ:CLRB) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Do institutionals & insiders hold more shares of CLRB or LVTX? 16.4% of Cellectar Biosciences shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to CLRB or LVTX? In the previous week, Cellectar Biosciences had 6 more articles in the media than LAVA Therapeutics. MarketBeat recorded 6 mentions for Cellectar Biosciences and 0 mentions for LAVA Therapeutics. Cellectar Biosciences' average media sentiment score of 0.49 beat LAVA Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cellectar Biosciences Neutral LAVA Therapeutics Neutral Which has more risk and volatility, CLRB or LVTX? Cellectar Biosciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Is CLRB or LVTX more profitable? LAVA Therapeutics' return on equity of -86.38% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A -619.70% -158.04% LAVA Therapeutics N/A -86.38%-34.12% Which has better earnings and valuation, CLRB or LVTX? LAVA Therapeutics has higher revenue and earnings than Cellectar Biosciences. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$44.58M-$21.92-0.22LAVA Therapeutics$11.98M2.99-$25.11M-$1.04-1.31 Do analysts recommend CLRB or LVTX? Cellectar Biosciences currently has a consensus target price of $375.00, suggesting a potential upside of 7,631.96%. LAVA Therapeutics has a consensus target price of $3.17, suggesting a potential upside of 132.84%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCellectar Biosciences beats LAVA Therapeutics on 8 of the 14 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.51M$10.41B$5.51B$8.95BDividend YieldN/A2.09%5.25%4.04%P/E Ratio-0.2216.4028.0220.16Price / SalesN/A31.20405.99173.08Price / CashN/A22.7937.0657.97Price / Book0.543.728.125.62Net Income-$44.58M$235.43M$3.16B$248.50M7 Day Performance0.60%2.31%3.14%4.49%1 Month Performance-55.82%2.59%3.48%7.03%1 Year Performance-93.12%-10.94%34.05%21.07% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences3.2889 of 5 stars$4.85+3.2%$375.00+7,632.0%-93.3%$8.51MN/A-0.2210LVTXLAVA Therapeutics1.798 of 5 stars$1.32flat$3.17+139.9%-28.0%$34.72M$4.99M-1.2760ATHEAlterity Therapeutics2.6357 of 5 stars$3.87-6.7%$12.00+210.1%+108.0%$34.32MN/A0.0010Gap DownTELOTelomir Pharmaceuticals2.1742 of 5 stars$1.15flat$15.00+1,204.3%-72.7%$34.22MN/A-2.741Gap UpRNTXRein TherapeuticsN/A$1.54+2.0%N/AN/A$34.12MN/A-0.549KALAKALA BIO3.6737 of 5 stars$5.28+3.5%$13.50+155.7%-11.4%$34.06M$3.89M-0.6430News CoverageLTRNLantern Pharma2.4939 of 5 stars$3.15-3.1%$25.00+693.7%-20.8%$33.96MN/A-1.7120News CoverageGap UpHigh Trading VolumeKZRKezar Life Sciences4.1568 of 5 stars$4.55-0.7%$39.50+768.1%-18.9%$33.26M$7M-0.4260Negative NewsOKUROnKure Therapeutics2.852 of 5 stars$2.39+0.4%$32.33+1,252.9%N/A$32.29MN/A-0.45N/AESLAEstrella Immunopharma2.2316 of 5 stars$0.88+0.2%$16.00+1,714.7%-22.1%$31.89MN/A-3.39N/ABDRXBiodexa PharmaceuticalsN/A$0.87+0.8%N/AN/A$31.63MN/A0.0020Upcoming EarningsGap Up Related Companies and Tools Related Companies LVTX Alternatives ATHE Alternatives TELO Alternatives RNTX Alternatives KALA Alternatives LTRN Alternatives KZR Alternatives OKUR Alternatives ESLA Alternatives BDRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
